Comparison of NT-ProBNP Changes in Heart Failure Patients Following ACEI vs ARB Therapy

NT-proBNP is a specific biomarker synthesized directly by the ventricular heart muscle under conditions of stretching or stress. The decrease in NT-proBNP levels correlates with clinical improvement in heart failure; a decrease exceeding the biological variation (>25%) indicates a good therapeutic response. Comparing effectiveness of ACEi and ARB therapies in outpatient heart failure patients in reducing NT-proBNP levels. This prospective study involved outpatient heart failure patients receiving ACEi or ARB therapy. Blood samples were taken at baseline and after two months of therapy from patients who met the inclusion criteria. The study included 27 subjects meeting inclusion criteria (13 ACEi group and 14 ARB group). The percentage change in NT-proBNP for ACEi was 29.47% (1.85 – 67.82) and for ARB was 40.53% (9.11-131.02), which was not statistically significant (p = 0.308). There were no significant changes in kidney function assessed by eGFR from baseline to post-therapy (p >0.05). The effectiveness of ACEi therapy compared to ARB in reducing NT-proBNP levels over two months was not significantly different.